Literature DB >> 23842098

Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry.

M Rowland1.   

Abstract

Entities:  

Year:  2013        PMID: 23842098      PMCID: PMC3733532          DOI: 10.1038/psp.2013.29

Source DB:  PubMed          Journal:  CPT Pharmacometrics Syst Pharmacol        ISSN: 2163-8306


× No keyword cloud information.
Wiley, 2012 430 p The publication last year of a textbook devoted to the theory and application of physiologically-based pharmacokinetic (PBPK) modeling and simulation in the pharmaceutical industry, by a scientist working in a pharmaceutical company, attests to the rapid emergence and recognition of the value of this mechanistic approach to drug selection and development. For the past 50 or so years, PBPK has been viewed primarily as an academic pursuit except within the area of risk assessment (to human) of environmental chemicals. This was driven by the need for a powerful predictive approach given the typical absence of human exposure data of many such compounds and the recognition by this community that empirical approaches alone are too limiting. That is not to say that physiological thinking has been absent in the interpretation and application of in vivo pharmacokinetic data by pharma; far from it. Moreover, mechanistic understanding of pharmacokinetic processes has grown by leaps and bounds during the past few decades as has quantitative in vitro–in vivo extrapolation of individual processes. What has been lacking is the wide adoption of dynamic mechanistic mathematical modeling of whole-body events, which requires the integration of a large body of systems-specific (physiological, anatomical, biochemical, and related) data with drug-specific data within the frame of complex but more realistic than empirical models. This book aims to address and help inform and hasten the use of PBPK models in preclinical and clinical drug development. The book is divided into two major sections: principles and methods, and applications. Covered in the first section is an introduction chapter to physiological methods in general, followed by ones on models of absorption, distribution, and elimination, as well as generic PBPK models, variability, uncertainty, and sensitivity analysis as applied to model building and use, and drug–drug interactions. Although much of this section is devoted to small molecules, it finishes with a welcomed and informative chapter on biologics, highly relevant given the increasing number of such drugs under development. Section 2 covers applications within the pharmaceutical industry, the integration of PBPK with pharmacodynamics, as well as PBPK modeling of populations; it finishes with a short chapter on the use of PBPK in drug discovery and development. Each chapter starts with a useful general introduction followed by an in-depth analysis, dealing with mechanistic and mathematical aspects of the topic, together with methodologies used to acquire the relevant information. At the end of each chapter is a helpful list of terms used with definitions, as well as an extensive list of references to help those readers wishing to pursue specific aspects in greater detail. The material is well organized, bringing together a large amount of information, and in general, explanations and development of the many equations are clear and well written. The book is also replete with examples as well as many informative tables and schematic flow charts that help the reader to understand and appreciate the place and industrial application of PBPK, as a compound moves from drug candidate selection and optimization through to early human investigation and clinical development. Given the complexity of PBPK models and the manifold-associated data, it is perhaps not surprising that the rise in industrial application can be traced to the growth and support of a variety of dedicated commercial PBPK software mentioned in the book. The author rightly stresses that nonetheless it is important that those applying the methodology should understand the concepts and methodologies underpinning PBPK, as well as its current limitations. A concern expressed by the author is that such software limits flexibility of a researcher in being able to modify some of the algorithms to explore the aspects not covered by the existing software. However, such persons are likely to be in the minority for if industrial application of PBPK models is to be routine and widespread, as the author wants, then the everyday needs will be met by ever-evolving commercial software. There is little to fault the book. In places the assumptions behind the equations are not fully stated, the reasoning on clinical impact of altered plasma protein binding may be open to some debate, that although thankfully relatively few there are the inevitable typos of a first printing, and some color in the figures would have been appreciated. The title of the book also does not fully convey its contents in that much of the last third of the book is devoted to pharmacodynamics (PD) and (PB)PK/PD, which is welcomed, although in a number of examples quoted to illustrate application, it is not clear that a PBPK, as against a compartmental PK, model was used by the investigators. That said, this book should be on the shelf and a companion to anyone seriously interested in mechanistic model-based drug development.

Conflict of interest

The author declared no conflict of interest.
  40 in total

1.  A physiologically based pharmacokinetic model for capreomycin.

Authors:  B Reisfeld; C P Metzler; M A Lyons; A N Mayeno; E J Brooks; M A Degroote
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Comment on: "A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood".

Authors:  Guo-Fu Li; Xiao Gu; Guo Yu; Shui-Yu Zhao; Qing-Shan Zheng
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

Review 3.  Network-based approaches in drug discovery and early development.

Authors:  J M Harrold; M Ramanathan; D E Mager
Journal:  Clin Pharmacol Ther       Date:  2013-09-11       Impact factor: 6.875

4.  Development of a decision tree to classify the most accurate tissue-specific tissue to plasma partition coefficient algorithm for a given compound.

Authors:  Yejin Esther Yun; Cecilia A Cotton; Andrea N Edginton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-11-21       Impact factor: 2.745

5.  Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes.

Authors:  Carrie German; Minu Pilvankar; Andrzej Przekwas
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-08-08       Impact factor: 2.745

6.  A physiome interoperability roadmap for personalized drug development.

Authors:  Simon Thomas; Katherine Wolstencroft; Bernard de Bono; Peter J Hunter
Journal:  Interface Focus       Date:  2016-04-06       Impact factor: 3.906

7.  The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update.

Authors:  Wenpeng Zhang; Yanyan Li; Peng Zou; Man Wu; Zhenqing Zhang; Tao Zhang
Journal:  AAPS J       Date:  2016-05-16       Impact factor: 4.009

8.  Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds.

Authors:  Rui Li; Tristan S Maurer; Kevin Sweeney; Hugh A Barton
Journal:  AAPS J       Date:  2016-03-07       Impact factor: 4.009

Review 9.  Multiorgan Microphysiological Systems for Drug Development: Strategies, Advances, and Challenges.

Authors:  Ying I Wang; Carlos Carmona; James J Hickman; Michael L Shuler
Journal:  Adv Healthc Mater       Date:  2017-12-04       Impact factor: 9.933

Review 10.  Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.

Authors:  Rui Li; Hugh A Barton; Manthena V Varma
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.